P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE. (1st July 2019) - Sink, Kaycee; Warren, Francis; Smith, Jillian; Schneider, Andres; Fuji, Reina N.; Quartino, Angelica; Mackey, Howard; Rabbia, Michael; Yule, Susan; Fontoura, Paulo; Doody, Rachelle; Ostrowitzki, Susanne